Current and reoccurring viral epidemic outbreaks such as those caused by Zika virus illustrate 10 the need for rapid development of antivirals. Such development would be immensely 11 facilitated by computational approaches that can provide experimentally testable predictions 12 for possible antiviral strategies. A key factor that has not been considered fully to date in the 13 study of antiviral targets is the high dependence of viruses to their host metabolism for 14 reproduction. Here, we focus on this dependence and develop a stoichiometric, genome-scale 15 metabolic model that integrates human macrophage cell metabolism with the biochemical 16 demands arising from virus production. Focusing this approach to currently epidemic viruses 17
INTRODUCTION 38
Rapid development of antiviral drugs for emerging and re-emerging viruses, such as the Zika 39 virus, remains a significant challenge (1, 2). Given that virus production within a host is 40 intertwined with host immune response and metabolism (3), it is suggested that novel 41 development of antivirals should take into account host processes (4, 5). Indeed, viruses are 42 entirely dependent on their hosts' cellular resources for their replication. This is highlighted 43 by observed variations in virus production levels correlating with cell-to-cell variance in 44 growth rate and phase (6), as well as virus infection leading to changes in host metabolism 45 (7) . In particular, virus infection leads to significant metabolic alterations in the host, in some 46 cases resulting in up to 3-fold increase in glycolysis rates (7-9) and changes in ATP 47 production rates (6). This observation can be seen as an emergent property of the combined 48 host-virus metabolic system and could be related to changes in host cellular demands arising 49 from viral production (10, 11). More specifically, alterations in host metabolism upon 50 infection can be understood as either viruses actively manipulating the host system to their 51 advantage (12), or the additional draw of metabolic components for viral production simply 52 resulting in a re-arrangement of host metabolic fluxes. 53 54 Regardless of its cause, the entanglement between host metabolism and viral production 55 opens up the possibility to perturb the former, as a way of limiting the latter (9, 12, 13). To 56 explore this possibility and towards understanding the potential interplay between host 57 metabolism and the additional 'virus demand' on it, stoichiometric genome scale metabolic 58 models and their optimisation through flux balance analysis (FBA) can provide ideal starting 59 points as they are demonstrated to allow analysis of cellular physiology as an interconnected 60 system (14, 15 ). Integration of virus production in a host metabolic model has already been 61 utilised to study the infection of bacteria with phage, indicating the presence of metabolic 62 limitations on phage replication depending on host's metabolic environment (16) . While this 63 type of stoichiometric metabolic analysis can potentially be applied to any host-virus pair, it 64 is particularly suited to Alpha-and Flavi-viruses. The rather simple physical and genomic 65 structure of these viruses (17, 18) allow straightforward construction of a pseudo biochemical 66 reaction representing their production from constituting parts. This pseudo reaction can then 67 subsequently be incorporated into a genome-scale metabolic model of any host. 68 69 Here, we develop and apply such an FBA approach to analyse host-virus metabolic 70 entanglement. Using a stoichiometric metabolic model of a human macrophage cell, we 71 establish an integrated virus-macrophage metabolic model for three viruses causing current 72 (or previously) epidemic outbreaks: Chikungunya virus (CHIKV); Dengue virus (DENV); 73 and Zika virus (ZIKV). These are representatives of the virus genera Alpha-(CHIKV) and 74
Flavi-virus (DENV, ZIKV), which are positive-sense single-strand RNA-viruses with rather simple physical structures (17, 18) . Viruses of both families have been observed to infect 76 monocyte derived macrophage cell lines (19) (20) (21) and are usually transmitted to humans via 77 arthropod vectors, the most common being mosquitos of the Aedes genus (22, 23). By 78 analysing the integrated metabolic model, we find that viral production results in significant 79 alterations in host metabolic fluxes. Subsequent analysis of this integrated model through 80 linear optimisation allows us to predict a set of host reactions, which when constrained can 81 inhibit virus production within the macrophage metabolic system. We show that this 82 prediction recovers most of the known targets of existing antiviral drugs, while highlighting a 83 set of hitherto unexplored reactions that either limit virus activity broadly or for a specific 84 virus. Thus, this computational approach allows rapid generation of experimentally testable 85 hypotheses for novel antiviral targets within a host cell. 86
87

RESULTS
88
Host metabolism displays alternative host-and viral-optimal states. We first used the 89 integrated virus-macrophage stoichiometric metabolic model to interrogate potential changes 90 in host metabolism upon virus infection. To do so, we considered two idealised scenarios; 91 one in which the metabolic system is optimised for the functional requirements of the host 92 cell as determined by a maintenance related biomass reaction (24) (host-optimal state), and 93 another in which the metabolic system is optimised solely for a biomass reaction that 94 represents the production of virus particles and that is derived from viral genomes (virus-95 optimal state) (see Methods and Figure S1 for details of virus biomass calculations). These 96 two states provide the theoretical extremes of a continuum of metabolic states that can arise 97 during virus infection. Whilst the first scenario aims to represent the normal physiological 98 state of macrophage cells, the second state represents a thought experiment of the host 99 metabolic fluxes being set for maximizing virus production. 100
To compare the host-and virus-optimal states of the model, we analyse the metabolic 101 fluxes directly feeding into the biomass pseudo reaction (see Supplementary Files S1 for 102 biomass reactions and S2 for flux values and ranges). As expected from linear optimisation, 103 we find that these fluxes reflect the stoichiometric differences in the amino acid and 104 nucleotide requirements of the host cell and the virus, thus achieving perfect fulfilment of 105 host or virus biomass requirements. We conclude that stoichiometric differences in metabolic 106 requirements for virus production vs. host maintenance, as summarised in Figure 1 which are shown to be subject to inaccuracies inherent in linear solvers used in flux balance 116 analysis (25). We find that the median of the allowed optimal metabolic flux ranges, between 117 host-and virus-optimal states, shows significant changes across subprocesses ( Figure 2 and 118 Supplementary File S2). In particular, the virus-optimal state displays significantly increased 119 median flux for reactions associated with lipid metabolism and nucleotide biosynthesis, and 120 significantly decreased flux for reactions associated with fatty acid biosynthesis and transport 121 (including intracellular transport reactions). Besides these general overall trends across 122 subprocesses, the virus-optimal state displays both increased or decreased median flux for 123 specific reactions within each subprocess (see pie charts in Figure 2 ). These changes are in 124 accordance with downstream requirements for fulfilling biomass requirements, and relate to 125 interconnections among sub-processes. For example, the reactions from the lipid metabolism 126 subprocess that show the most increase in their median fluxes (compared to host) involve 127 ADP/ATP and phosphor, which are metabolites that link directly into the reactions of the 128 nucleotide biosynthesis subprocess (and feeding into increased nucleotide requirement in the 129 virus, see Figure 1 ). 130
The specific changes in the allowed flux ranges also highlight potential physiological 131 changes. As an illustrative example, we show the extent of changes within the glycolysis 132 pathway, where allowed flux ranges that can sustain virus-optima are wider compared to 133 those that can sustain host-optima ( Figure 2 ). The allowed ranges for glucose and oxygen 134 uptake indicate that virus-optima can be sustained even under low uptake fluxes, indicative of 135 the potential feasibility of anaerobic metabolism still sustaining virus production (26). Taken 136 together, this comparison of host-and virus-optimal states show that the differences within 137 the stoichiometric requirements of the different viruses and between the host cause large-138 scale alterations in the host metabolic fluxes. 139 140 Enforcing host-optimal flux ranges on individual reactions in the model predicts 141 antiviral targets that can suppress viral production. As the host-optimal and virus-optimal 142 flux ranges within the integrated model differ, we hypothesize that the model can be 143 constrained in a way to limit viral production (see Methods). To test and utilise this 144 hypothesis, we use the integrated stoichiometric model to identify the host reactions, which, 145 when constrained limit virus production the most. This analysis can be implemented in 146 different ways, for example through constraining of flux values to zero (i.e. reaction 'knock-147 outs'). Applying such knock-outs, we find several reactions that limit virus-optima, but all of 148 these also results in significant reduction in host-optima (Supplementary File S3). To identify 149 if there any reactions that can perturb virus production, whilst maintaining the host viability, 150 we constrained reaction fluxes to ranges that are derived from the FVA described above. In 151 particular, we identified flux ranges that still allowed for the attainment of the host-optimal 152 state, but were outside of the range allowed by the virus-optimal state (see Methods). 153
This approach highlights a set of reactions that result in different levels of reductions 154 in the virus optima of CHIKV, DENV or ZIKV, while not affecting the host-optima (as 155 expected from the way we set the flux constraints, see Methods). We identify 29 reactions 156 that can reduce the virus optima to below 80% of the original value for at least one virus 157 These identified reactions are potential antiviral targets, in the sense that altering their 164 fluxes can limit virus production within the host. Thus, we explored if these reactions match 165 with known antiviral drug targets. Performing a literature analysis, we found that there are 166 currently 10 antivirals, specific to RNA-viruses, and these target only 5 unique metabolic 167 enzymes (see Supplementary Table 1 ). Of these 5 drug targets (and the associated drugs) one 168 has been experimentally verified to be effective against CHIKV ( Inositol-5'-monophosphate 169 dehydrogenase; IMPD) (27); and another against DENV (Dihydroorotate Dehydrogenase; 170 DHORD9) (28) . Whilst the other three targets have been verified to be effective against a 171 number of RNA viruses (29), they are yet to be tested against CHIKV, DENV and ZIKV. 172
We found that out of these 5 known antiviral targets, all are implicated in our 173 analysis. The three known antiviral target reactions involving the genes IMPD (27); 174 DHORD9 (28); and Orotidine-5'-phosphate Decarboxylase (OMPDC) (29) are found to perturb virus optima for all viruses (Figure 3 ). The antiviral target S-adenosylhomocysteine 176 hydrolase (AHC) (29) is predicted to effect only CHIKV optima, and only to a level higher 177 than the 80% cut-off we used in the above analysis (we note that setting AHC reaction flux to 178 zero abolishes virus growth for all three viruses (see Supplementary File S3) ). Finally, CTP 179 synthase, which has been indicated to exhibit an effect on several RNA viruses (29), is 180 included in the model as two reactions which perform the same reaction utilising either 181 ammonia (mediated by CTPS1) or glutamine (mediated by CTPS2) as a nitrogen source (30) 182 and therefore not highlighted in our initial flux enforcement analysis focusing on single 183 reactions. When we constrain both reactions associated with these two reactions 184 simultaneously at host-derived flux ranges, a reduction in all virus optima is observed. We present a computational approach that combines application of FBA and FVA with 242 development of integrated host-virus metabolic models. We show that this novel approach 243 recovers the known metabolic antiviral targets within a human macrophage cell and predicts 244 new potential targets. These predicted reactions fall primarily onto pathways involving 245 nucleotides and amino acids that are differentially used by the host and virus. The results of 246 this study are in line with an integrated perspective that views the virus as an additional 247 metabolic burden on the host cells that could be met or avoided by tinkering of host 248 metabolic fluxes. The observed overlap between predicted reactions and known antiviral 249 drugs gives confidence to this integrated modelling approach and highlights its potential as a 250 rapid prediction tool to guide experimental design. This can be especially useful in the case 251 Generation of virus biomass objective functions. To implement the FBA approach to 278 studying virus infections from a metabolic stance, we define a pseudo reaction accounting for 279 the production of virus particles from its constituents. We call this reaction a virus biomass 280 objective function (VBOF). To account for metabolic fluxes associated with the virus 281 production, the VBOF needs to capture the stoichiometry of nucleotide, amino acid and 282 associated energy metabolites relating to virus production, similar to biomass production 283 function used for microbial metabolic models (37). We derive the metabolic stoichiometry of 284 virus production from the viral genome sequence, the subsequently encoded proteins, the 285 copy number of those proteins, and knowledge of the energetic requirements for peptide 286 bonds and phosphodiester bonds. Details of this derivation is given below, while a schematic 287 of VBOF generation is included as Figure S1 . Classification System (39), and depending on this classification, a viral particle may contain 294 more than a single copy of the genome. This is factored into the calculation of the nucleotide 295 counts. In the presented study, all studied viruses fall into Group IV classification: they 296 replicate their positive single-stranded RNA (+ssRNA) genome via a negative ssRNA (-297 ssRNA) intermediate. Therefore, the counts of the nucleotides in the negative strand is equal 298 to the counts of the complementary nucleotide in the positive strand, i.e. count of A on (+/-) 299 strand = count of U on (-/+) strand, and similarly for G and C counts. The count for each 300 RNA nucleotide (Adenosine (A), Cytidine (C), Guanine (G) and Uracil (U)) can be taken 301 directly from the virus genome sequence: RNA utilises Uracil (U) in place of Thymine (T), 302 therefore T must be replaced with U from the genome sequence readout. In this study, all the 303 viruses have two categories of polyproteins that compose the proteome: structural and non-304 structural. The amino acid sequence of these two polyproteins, and indeed any genome 305 derived protein sequences, are obtained from gene annotations of the viral genomes as 306 provided in the NCBI genome entries (see above for NCBI entries used). The different sub-307 categories of the viral proteome may be differentially incorporated into a single virus particle. 308
For the viruses studied here, the structural and non-structural polyproteins are expressed in a 309 ratio that is derived from the overall virus structure (i.e. proteins in the capsid, nucleocapsid, 310 etc.)(18). The ratio is 1:240 for CHIKV(18), and 1:180 for DENV/ZIKV (17). More broadly, 311 the ratio of different protein classes in a single virus particle can be derived from the overall 312 virus structure or directly from literature / experimental evidence. As ATP is hydrolysed in this process, the water requirement for polymerisation ? @ $ is 345 equal to that of ATP. The products from the hydrolysis of ATP (ADP, P i and H + ) are also 346 accounted for in the VBOF (see Equation 16 ). 347 integrated models were optimised and reaction fluxes predicted using the linear optimisation 396 approach known as flux balance analysis (FBA) (43). Linear optimisation is a mathematical 397 technique that optimises a given function under a set of constraints defined by mathematical 398 inequalities. In the context of metabolic models, the constraints correspond to limitations on 399 reaction fluxes, while the function to be optimised can be defined as the flux in a specific 400 reaction. While several biologically plausible objective functions can be defined (44), a 401 common approach is to define a pseudo reaction that describes biomass production from its 402 constituent parts, and then optimise the flux to this reaction, as we have done here. Since the 403 set of constraints includes constraints on uptake reactions, this application of FBA results in 404 prediction of optimal biomass production flux with respect to a specific uptake flux. In other 405 words, FBA optimises for biomass yield from given substrates assumed to be present in the 406 media. In this work, we apply FBA to optimise a combined host-virus metabolic system 407 satisfy either the host or virus objective function (as described above) and study the resulting 408 flux predictions. 409
Calculating pyrophosphate (PP i ) liberation from nucleotide polymerisation (mmol
To simulate a virus-optimal state, the models are optimised using the respective 410 VBOFs of CHIKV, DENV and ZIKV viruses as the objective function, while to simulate a 411 host-optimal state the models are optimised using the existing biomass maintenance reaction 412 for the human macrophage as presented in (24). Besides running linear optimisation to find 413 the optimal flux sets under each scenario, we have also performed a flux variability analysis 414 (FVA) (45), which provides flux ranges for each reaction that still would allow attainment of 415 a given host/virus optima. The FVA approach is shown to be more robust to instabilities 416 associated with prediction and comparison of a single optimal flux sets (41). For each 417 reaction in the model we compared the resulting flux ranges from FVA under host and virus 418 optimisation, by evaluating the mean value of the allowed flux range for each individual 419 reaction (A i ) and then collating the mean flux values for reactions associated with given 420 subprocesses (aggregated subsystems) as a percentage of total flux through that process. 421
More formally, we define the differential distribution of reaction flux for each subprocess (i) 422 between the host and virus optimised models in terms of a fold-change: 423 optimal state can be altered by specific constraints in the host model. To evaluate the impact 452 of having different VBOFs on the outcome of such an analysis, we have generated a range of 453 VBOFs that were either derived from the original VBOFs or were completely randomly 454 generated. To evaluate impact of small deviations from the original VBOFs, we generated 455 variants of the original virus genomes through nucleotide substitution; for each virus we 456 generated 1000 genome variants, where each variant contained 1, 2, 3, 4, 5 or 10 nucleotide 457 substitutions. For the subsequent VBOF generation from these variant genomes, the genome 458 and protein copy numbers were kept as in the original. To evaluate more variant VBOFs, we 459 generated another 1000 genomes for each virus that were created from the original genome 460 with a random number (between 0 and the total length of the genome) of nucleotide 461 substitutions, and using randomly drawn structural and non-structural polyprotein copy 462 numbers per virus particle. Finally, and in an attempt to generate a set of VBOFs that are far 463 removed from the original ones, both in terms of genome sequence and the structural and 464 non-structural protein numbers, we directly generated random VBOFs. We between the host and virus biomass objective functions. The differential usage was calculated 516 against all biomass precursors. Comparison was conducted for all 20 amino acids, and 4 517 RNA nucleotides (the x-axes are labelled with the common short notations for these). All 518 calculations and biomass formulations are as described in the Methods, and all biomass 519 stoichiometric values are provided as Supplementary File S1. Supplementary File S4) . 541
Abbreviations used for the compounds and reactions are as in Supplementary Table S2 and 542 S3 respectively. Some of the identified reactions are interconnected, forming pathways. 543 pyrimidine synthesis; Purple, pentose phosphate pathway; Blue, purine synthesis; Green, 545 nucleotide biosynthesis. The starting metabolites into these pathways, Glutamine and D-546
Ribose 5-phosphate, are derived from glutamine biosynthesis and pentose phosphate 547 pathways. Reactions targeted by a known antiviral or inhibitor are marked by white and red 548 filled stars and circles, respectively. Complete list of antiviral compounds from which the 549 matches were obtained are provided as Supplementary Table S1 . outlines the process of forming the necessary components for the pseudo-reaction that 597 represents the production of virus particles (biomass). 598
